Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults.

by
Only the 110mg and 150mg capsules of Pradaxa (dabigatran) are licensed for the new DVT and PE indications.
Only the 110mg and 150mg capsules of Pradaxa (dabigatran) are licensed for the new DVT and PE indications.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package